FG
NVO

Fairman Group’s Novo Nordisk NVO Stock Holding History

Fairman Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02K Hold
63
– – ﹤0.01% 253
2026
Q1 		$2.39K Hold
63
– – ﹤0.01% 271
2025
Q4 		$3.21K Hold
63
– – ﹤0.01% 251
2025
Q3 		$3.5K Buy
+63
New +$3.69K ﹤0.01% 209

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Fairman Group's NVO Position: Q2 2026 in Review

Fairman Group held its Novo Nordisk (NVO) position steady in Q2 2026 at 63 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #253.

Fairman Group first reported a position in NVO in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.5K in Q3 2025. 800 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Fairman Group held 63 shares of Novo Nordisk worth $3.02K as of Q2 2026.
  • Fairman Group left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Fairman Group's portfolio in Q2 2026, its #253 holding.
  • Fairman Group first reported a position in Novo Nordisk in Q3 2025 and has held it in 4 quarters since.
  • Fairman Group's Novo Nordisk position peaked at $3.5K in Q3 2025.
  • 800 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.